The Indian start-up LaBelforte has spear its special purpose business entities, Covidrops and Covinhaler, to facilitate the development of immune-optimized nasal and inhaled pharmaceuticals to treat Covid-19.
The two entities will contribute to the development of these products to follow global progress in the development of the second generation of therapies for Covid-19.
The company expects that drug products that target local immune response engagement at the nose and oral cavity, common entry points for the virus, could add a new dimension to the global response to the pandemic.
LaBelforte Founder, Dr. Gaurav Raj Chhabra, said: “The company’s goal is primarily to facilitate the co-development of nasal sprays and pocket inhalers that are safe and effective adjuncts for prophylaxis and covid-19 therapy.
“Our immediate focus is on host-directed therapeutic options that safely and effectively optimize mucosal and barrier immunity by potentiating the body’s immune system through immunogenic gene expression.”
Intranasal/inhaled drug products, which enhance mucosal immunity as a first-line barrier to viral entry and excretion, can advance disease control and prevention.
The company plans to launch its products through Covidrops and Covinhaler in India by the second quarter of this year, after obtaining all required regulatory approvals and with the consent of relevant industry alliances.
LaBelforte’s Head of Business Development and Co-Founder Sanwale said, “In the first phase, we primarily focused on developing appropriate collaborations globally to seek out the most promising new candidates being developed. research, explore a reoriented drug approach and lay the groundwork for intellectual property.
“Then, as we move forward, we might as well opt for strategic alliances in the main pharma industry for a smooth transition from lab to market.”